Stem Cell Therapy for Epidermolysis Bullosa-Does It Work?

J Invest Dermatol 2016 11;136(11):2119-2121

Department of Dermatology and Cutaneous Biology, Sidney Kimmel Medical College at Thomas Jefferson University, Philadelphia, Pennsylvania, USA; Jefferson Institute of Molecular Medicine, Thomas Jefferson University, Philadelphia, Pennsylvania, USA. Electronic address:

Epidermolysis bullosa is a group of heritable skin fragility disorders with considerable morbidity and mortality. It is known to be caused by mutations in as many as 18 distinct genes, but there is no specific or effective treatment. Preclinical developments of gene correction, protein replacement, and cell-based approaches for treatment have suggested new therapeutic avenues, and some of them, including bone marrow transplantation and mesenchymal stem cell therapy, have entered into early clinical trials. Hammersen et al. report on two patients with severe generalized junctional epidermolysis bullosa treated with allogeneic stem cell therapy, but with little success. Careful examination of the existing literature suggests that current approaches of cell-based therapies may be helpful in ameliorating some of the clinical features and symptoms in these patients, but advanced strategies, with improved safety profiles, are required for development of durable therapy for these currently intractable disorders.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jid.2016.07.004DOI Listing
November 2016
46 Reads

Publication Analysis

Top Keywords

stem cell
12
cell therapy
12
epidermolysis bullosa
8
careful examination
4
replacement cell-based
4
examination existing
4
cell-based approaches
4
success careful
4
suggested therapeutic
4
therapy success
4
treatment suggested
4
protein replacement
4
approaches treatment
4
existing literature
4
current approaches
4
preclinical developments
4
approaches cell-based
4
developments gene
4
suggests current
4
correction protein
4

Similar Publications